1. Medtech Insight

Renal Denervation Round 2: Medtronic, Boston Sci Move Ahead With Studies

Medtronic and Boston Scientific are getting set to launch new trials of their renal denervation technologies, both believing they can overcome the problems that caused Medtronic's SYMPLICITY HTN-3 sham-controlled trial to miss its primary endpoint last year.

Medtronic PLC is hoping to use lessons learned from the SYMPLICITY HTN-3

trial, which failed to meet its primary endpoint, in a planned study of its second-generation Symplicity Spyral renal denervation

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Archive

More from Medtech Insight